company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24601000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24601000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,24601000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8398000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,38615000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,47013000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22412000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,642000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-24000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,618000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21794000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,908000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22702000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22702000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22702000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.55
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.55
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41520000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q2,2009-04-01,2009-06-30,2010-08-05 16:53:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.55
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24249000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24249000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,24249000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10680000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23219000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33899000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9650000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-100000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-10000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-110000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9760000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-552000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9208000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9208000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9208000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41708000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2009.0,Q3,2009-07-01,2009-09-30,2010-11-04 17:27:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24564000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24564000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,24564000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11170000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35870000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11306000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-988000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-999000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12305000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,18000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12323000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12323000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12323000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42500000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.29
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42500000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41870000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q1,2010-01-01,2010-03-31,2011-05-05 08:00:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,26617000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,26617000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,26617000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10107000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,28136000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,38243000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11626000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3278000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,43000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3235000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14861000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-229000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14632000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14632000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14632000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.35
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.35
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,0.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q2,2010-04-01,2010-06-30,2011-08-03 08:30:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.35
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,27668000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,27668000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27668000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8928000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27468000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,36396000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8728000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-624000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,20000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-604000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9332000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,298000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9630000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9630000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9630000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42123000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 16:58:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21192000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21192000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21192000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7522000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,26080000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33602000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12410000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-444000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,6351000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5907000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6503000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,427000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6930000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6930000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6930000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42040000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2010.0,Q4,2010-10-01,2010-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20897000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20897000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20897000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10224000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,26349000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,36573000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15676000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-690000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,81000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-609000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16285000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16285000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16285000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16285000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.38
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.38
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42345000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 17:01:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.38
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20614000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20614000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20614000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8429000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25303000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33732000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13118000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-690000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-16000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-706000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13824000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13824000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13824000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13824000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.33
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.33
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42379000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:00:40+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.33
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20791000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20791000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20791000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8955000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24274000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33229000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12438000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-202000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-597000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-799000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13237000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13237000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13237000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13237000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.31
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.31
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42654000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 17:15:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.31
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20455000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20455000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20455000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10672000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23369000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34041000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13586000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-718000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-717000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14303000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14303000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14303000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14303000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42400000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42400000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42410000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20587000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20587000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20587000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10406000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21074000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31480000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10893000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-666000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,191000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-475000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11368000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11368000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11368000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11368000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45500000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45500000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46210000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 17:00:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20884000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20884000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20884000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11228000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21723000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,32951000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12067000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-868000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-21000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-889000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12956000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12956000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12956000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12956000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51280000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 08:08:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16759000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16759000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16759000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12812000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22094000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34906000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18147000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1352000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1355000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19502000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19502000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19502000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19502000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.38
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.38
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51542000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 08:18:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.38
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8495000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8495000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8495000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10166000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21678000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,65000000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,96844000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-88349000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-659000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,16248000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,15589000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-72760000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-10572000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-62188000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-62188000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-62188000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50200000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.23
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50200000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.23
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50286000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.23
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18642000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18642000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18642000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6267000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22179000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28446000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9804000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,224000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,5000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,229000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9575000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-562000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9013000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9013000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9013000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,60100000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,60100000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,59173000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:35:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8687000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8687000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8687000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5784000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24215000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29999000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21312000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,270000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,259000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21053000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2884000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18169000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18169000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18169000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,62700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.29
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,62700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,61661000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 08:37:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8991000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8991000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8991000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6768000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,34457000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41225000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32234000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,290000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-12000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,278000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-31956000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2270000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-29686000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-29686000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-29686000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,61800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.48
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,61800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.48
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,62416000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 08:30:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.48
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10847000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10847000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10847000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8333000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,32106000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,40439000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29592000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,285000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-29000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,256000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-29336000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3021000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32357000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32357000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-32357000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,61500000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.53
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,61500000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.53
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,61551000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.53
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8275000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8275000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8275000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8925000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,268414000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,277339000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-269064000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,333000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-82000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,251000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-268813000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-17870000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-250943000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-250943000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-250943000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,67800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.7
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,67800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.7
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,67786000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 08:13:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.7
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7295000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7295000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7295000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11518000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,40782000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,52300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-45005000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,693000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-77000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,616000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-44389000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-315000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-44074000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-44074000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-44074000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,76000000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.58
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,76000000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.58
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,75835000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 07:58:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.58
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10972000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10972000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10972000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9898000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,46273000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,56171000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-45199000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,753000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,524000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1277000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-43922000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,67000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-43989000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-43989000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-43989000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,75800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.58
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,75800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.58
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,76408000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:44:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.58
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24019000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24019000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,24019000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14185000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,55546000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,69731000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-45712000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,780000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1452000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2232000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-43480000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-22091000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21389000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21389000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21389000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,74300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.01
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,74300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.01
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,74278000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.01
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18537000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18537000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18537000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12724000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,58035000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,70759000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-52222000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1014000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1014000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-51208000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-431000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-50777000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-50777000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-50777000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,81900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.62
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,81900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.62
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,82074000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:46:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.62
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8685000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8685000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8685000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14622000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,67007000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,81629000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-72944000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1619000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1592000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-71352000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,431000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-71783000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-71783000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-71783000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,84500000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.85
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,84500000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.85
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,84353000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:47:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.85
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6324000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6324000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6324000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,16036000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,68618000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,84654000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-78330000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1610000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-72000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1538000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-76792000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-76792000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-76792000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-76792000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,84400000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.91
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,84400000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.91
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,84633000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:03:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.91
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7551000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7551000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7551000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17228000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,82835000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,100063000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-92512000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1616000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,175000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1791000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-90721000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-90721000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-90721000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-90721000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,84100000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.07
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,84100000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.07
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,83992000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.07
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7345000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7345000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7345000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,21100000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,96273000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,117373000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-110028000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1813000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,5241000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,7054000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-102974000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-102974000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-102974000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-102974000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,85100000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.21
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,85100000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.21
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,85277000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 08:36:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.21
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8709000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8709000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8709000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17987000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,83172000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,101159000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-92450000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2092000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,229000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2321000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-90129000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-90129000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-90129000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-90129000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,85800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.05
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,85800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.05
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,85545000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:31:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.05
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13651000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13651000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13651000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,22391000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,97936000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,120327000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-106676000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2204000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,401000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2605000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-104071000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-104071000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-104071000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-104071000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,86000000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.21
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,86000000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.21
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,85716000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:31:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.21
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,17454000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,17454000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17454000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,27876000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,105011000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,132887000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-115433000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2199000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2499000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-112934000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-112934000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-112934000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-112934000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,85600000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.32
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,85600000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.32
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,85596000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.32
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18960000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18960000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18960000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,38487000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,86984000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,125471000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-106511000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2128000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2907000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-779000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-107290000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-107290000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-107290000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-107290000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,85800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,85800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,86027000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 17:04:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.25
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15932000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15932000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15932000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,45779000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,90627000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,136406000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-120474000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2577000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-523000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2054000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-118420000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-118420000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-118420000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-118420000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,88400000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,88400000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,88098000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 08:46:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,17096000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,17096000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17096000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,47644000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,95252000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,142896000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-125800000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3296000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-433000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2863000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-122937000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-122937000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-122937000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-122937000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,91700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,91700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,91828000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:32:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.34
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,37924000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,37924000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,37924000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,67455000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,117772000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,185227000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-147303000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4235000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,841000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5076000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-142227000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-142227000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-142227000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-142227000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,90600000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.49
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,90600000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.49
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,90554000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.49
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21899000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21899000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21899000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,72447000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,96857000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,169304000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-147405000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5794000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,335000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,6129000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-141276000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-62000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-141214000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-141214000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-141214000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,100200000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.41
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,100200000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.41
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,99979000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 16:31:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.41
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,29907000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,29907000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,29907000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,84679000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,137582000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,222261000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-192354000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,6101000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,22772000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,28873000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-163481000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,79000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-163560000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-163560000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-163560000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,100300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.63
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,100300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.63
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,100519000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:19:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.63
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2069000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2069000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,137000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,137000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1932000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,116545000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,139945000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,256490000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-254558000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,6796000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2925000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,9721000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-244837000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,445000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-245282000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-245282000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-245282000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,100900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.43
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,100900000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.43
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,100783000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:03:40+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.43
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21033000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21033000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1665000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1665000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19368000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,108688000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,131036000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,239724000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-220356000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10571000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1295000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,9276000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-211080000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,361000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-211441000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-211441000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-211441000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,100600000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.1
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,100600000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.1
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,100590000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.1
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33294000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33294000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3347000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3347000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,29947000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,89608000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,129127000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,218735000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-188788000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7525000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,43000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,7568000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-181220000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,695000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-181915000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-181915000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-181915000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,105200000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.73
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,105200000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.73
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,105400000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 08:47:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.73
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,44714000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,44714000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4326000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4326000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,40388000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,112769000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,163890000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,276659000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-236271000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8781000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,8969000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,17750000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-218521000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,960000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-219481000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-219481000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-219481000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,108700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.02
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,108700000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.02
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,108576000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:19:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.02
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,70061000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,70061000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5213000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5213000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,64848000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,120351000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,160796000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,281147000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-216299000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,9889000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2519000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,7370000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-208929000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-394000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-208535000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-208535000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-208535000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,108600000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.92
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,108600000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.92
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,108701000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:03:40+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.92
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,71681000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,71681000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12176000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12176000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,59505000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,156277000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,201301000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,357578000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-298073000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7253000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,14237000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,21490000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-276583000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-398000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-276185000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-276185000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-276185000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,109300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.44
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,109300000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.44
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,109264000.0
Alnylam Pharmaceuticals Inc,ALNY,,0001178670,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.44
